VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Abp 501-hcf
Phase 1
Amgen
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[2]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Adalimumab
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Adalimumab
Phase 1
Completed
Clinical
Trials by Indication
[1]
Adalimumab
1 trial
A Randomized, Single-blind, Single-dose, 2-arm, Parallel-group Study to Determine the Pharmacokinetic Comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF) in Healthy Adult Subjects
Completed
·
Amgen
·
Phase 1
·
NCT05909852
·
372 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Abp 501-hcf. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform
—
Drug–disease associations for Abp 501-hcf. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR
—
Amgen company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Highest Phase
Phase 1
[1]
Company
Amgen
Related News
